Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer

Published on 01 Sep 2023
Last Updated on 02 Jan 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Olaparib 100 mg and 150 mg tablets as adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy. Maximum duration of treatment: 1 year.

Funding status

Olaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 March 2024.

Clinical indication, subsidy class and MediShield Life claim limit for olaparib are provided in the Annex.

Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer (Updated 2 Jan 2024) [PDF, 266 KB]

PES Olaparib for BRCA-mutated HER2-negative early breast cancer (Updated 2 Jan 2024) [PDF, 93 KB]